

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces that its founding members Markku Jalkanen, a director of the Company, and his spouse Sirpa Jalkanen have on 3 June 2025 donated 500,000 ordinary shares in the Company to the Finnish Foundation that bears their name (Sirpa ja Markku Jalkasen Säätiö, Business ID 1729345-2) (the “Foundation”). Markku Jalkanen donated 400,000 ordinary shares and Sirpa Jalkanen donated 100,000 ordinary shares.

The purpose of the Foundation is to promote and support high-quality medical research in Finland, and the donors want to support the realization of the Foundation's purpose with this donation. The Foundation is independent of Markku and Sirpa Jalkanen. Following receipt of the donation, the Foundation will be interested in 500,000 ordinary shares in the Company, representing approximately 0.45 per cent. of the total voting rights in the Company. In addition, on 3 June 2025, Markku and Sirpa Jalkanen have sold in aggregate 300,000 ordinary shares in the Company. Markku Jalkanen sold 200,000 ordinary shares and Sirpa Jalkanen sold 100,000 ordinary shares.

Further details are set out in the Notification of Dealing Form below.

Director/PCA	Holding prior to sale/disposal	Number of ordinary shares sold / disposed	Resultant interest in ordinary shares in the Company	Resultant percentage of voting rights in the Company
Markku Jalkanen	2,225,266	600,000	1,625,266	1.45%
Sirpa Jalkanen	1,188,168	200,000	988,168	0.88%

Following the above transactions, the aggregate holdings of Markku and Sirpa Jalkanen amount to 2,613,434 ordinary shares in the Company, representing approximately 2.33 per cent. of the voting rights in the Company.

For more information, please contact:

IR Partners, Finland (Media)	+358 44 313 5005 riina.tuominen@irpartners.fi
Riina Tuominen	+358 50 553 9535 / +44 7 469 766 223
Kare Laukkanen	kare.laukkanen@irpartners.fi
FINN Partners, US (Media)	+1 847 791-8085
Alyssa Paldo	alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker)	+44 (0) 207 213 0880
Sandy Jamieson, Jo Turner	
Sisu Partners Oy (Certified Adviser on Nasdaq First North)	+358 (0)40 555 4727
Juha Karttunen	+358 (0)50 553 8990
Jukka Järvelä	

About *bexmarilimab*

Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. *Bexmarilimab* binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, *bexmarilimab* alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is *bexmarilimab*, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. *Bexmarilimab* is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1	Details of the person discharging managerial responsibilities/person closely associated	
a.	Name	Markku Jalkanen Sirpa Jalkanen
2	Reason for notification	Ä
		Non-executive Director

a.	Position/Status	PCA		
b.	Initial notification/ Amendment	Initial Notification		
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a.	Name	Faron Pharmaceuticals Ltd.		
b.	LEI	7437009H31TO1DC0EB42		
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a.	Description of the financial instrument, type of instrument	Ordinary Shares		
	Identification Code	ISIN: FI4000153309		
b.	Nature of the transaction	Disposal of ordinary shares		
		Â	Price(s) per share (p)	Volume(s)
			Nil	400,000
			â,-3.09816	200,000
			Nil	100,000
			b) â,-3.0039	b) 100,000
d.	Aggregated information Volume Price	Transaction details (a) (1): Volume 36,773 Unit price: 3.18 EUR (2): Volume 63,227 Unit price: 3.20 EUR (3): Volume 32,006 Unit price: 3.09 EUR (4): Volume 27,875 Unit price: 2.95 EUR (5): Volume 26,594 Unit price: 2.98 EUR (6): Volume 5,000 Unit price: 3.07 EUR (7): Volume 8,525 Unit price: 2.89 EUR Transaction details (b) (1): Volume 32,006 Unit price: 3.09 EUR (2): Volume 27,875 Unit price: 2.95 EUR (3): Volume 26,594 Unit price: 2.98 EUR (4): Volume 5,000 Unit price: 3.06 EUR (5): Volume 8,525 Unit price: 2.89 EUR		
e.	Date of the transaction	03/06/2025		
f.	Place of the transaction	Nasdaq First North Growth Market		